Analysis of Ian 5 Function
Analysis of Ian 5 Function
批准号:
6990076
负责人:
Hartmut Karl-Heinz Weiler
金额:
$8.87万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2005
资助国家:
美国
项目状态:
已结题
起止时间:
2005-07-01 至 2010-01-31
中文摘要
点击翻译按钮获取中文摘要
英文摘要
The identification of the Ian5 gene as the candidate Iddm2/lyp gene as has opened a new set of questions addressing the particular function of this gene in lymphopenia and its relation to the development of autoimmune diabetes. The knowledge about of Ian5, and of the other members of this gene family is still fragmentary, but seems to involve common themes, such as the ability to regulate apoptosis, to bind GTP, and to by associated with immune cells. It is not known how these emerging activities of Ian 5 are tied to the development of lymphopenia and type 1 diabetes, and whether both lymphopenia and autoimmune diabetes are merely epiphenomena or are indeed causally linked. Evolutionary divergence of the Ian gene family has further led to the presence of a paralog of Ian5, termed Ian4, in both humans and mice, but not in rats. Here,
we investigate the specific function of the first identified candidate iddm2 gene, Ian5, in the development of immune diabetes. Specifically, we will utilize transgenic rescue of the lyp-phenotype in BB-DP rats to establish formal proof that the loss of Ian5 function is the sole cause of lymphopenia and autoimmune diabetic disease; Second, we will generate a mouse model of Ian5 deficiency and test the hypothesis that Ian5 prevents lymphopenia and autoimmune disease by inhibiting apoptosis of regulatory T cells induced by the ART2/Rt6-dependent activation of the P2X7 receptor by ribosylated nucleotides. Third, in order to gain first insights into the molecular interactions that couple Ian5 function to the inhibition of apoptosis and autoimmune disease, we will conduct an in vivo structure-function analysis of Ian5. Results from these experiments are expected to delineate the molecular and pathophysiological mechanism that control the survival of regulatory T cells and lead to autoimmune diabetes.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Core B: Glyco-genomics and Bioinformatics
-
批准号:10321578
-
项目类别:
-
资助金额:$23.27万
-
财政年份:2021
-
负责人:Hartmut Karl-Heinz Weiler
-
依托单位:
Core B: Glyco-genomics and Bioinformatics
-
批准号:10545007
-
项目类别:
-
资助金额:$25.86万
-
财政年份:2021
-
负责人:Hartmut Karl-Heinz Weiler
-
依托单位:
Core B: Glyco-genomics and Bioinformatics
-
批准号:10088966
-
项目类别:
-
资助金额:$27.25万
-
财政年份:2021
-
负责人:Hartmut Karl-Heinz Weiler
-
依托单位:
Core C: Animal Models Core
-
批准号:10379434
-
项目类别:
-
资助金额:$14.81万
-
财政年份:2019
-
负责人:Hartmut Karl-Heinz Weiler
-
依托单位:
Core C: Animal Models Core
-
批准号:10113375
-
项目类别:
-
资助金额:$16.54万
-
财政年份:2019
-
负责人:Hartmut Karl-Heinz Weiler
-
依托单位:
Core C: Animal Models Core
-
批准号:10584532
-
项目类别:
-
资助金额:$16.44万
-
财政年份:2019
-
负责人:Hartmut Karl-Heinz Weiler
-
依托单位:
Regulation of Innate Immunity by Coagulation Receptors
-
批准号:9279265
-
项目类别:
-
资助金额:$41.75万
-
财政年份:2016
-
负责人:Hartmut Karl-Heinz Weiler
-
依托单位:
Regulation of Innate Immunity by Coagulation Receptors
-
批准号:9158877
-
项目类别:
-
资助金额:$41.75万
-
财政年份:2016
-
负责人:Hartmut Karl-Heinz Weiler
-
依托单位:
Protein C pathway function in hematopoiesis
-
批准号:9037703
-
项目类别:
-
资助金额:$41.75万
-
财政年份:2014
-
负责人:Hartmut Karl-Heinz Weiler
-
依托单位:
Protein C pathway function in hematopoiesis
-
批准号:8669684
-
项目类别:
-
资助金额:$41.75万
-
财政年份:2014
-
负责人:Hartmut Karl-Heinz Weiler
-
依托单位:
Protein C pathway function in hematopoiesis
-
批准号:9229562
-
项目类别:
-
资助金额:$41.75万
-
财政年份:2014
-
负责人:Hartmut Karl-Heinz Weiler
-
依托单位:
Mechanism of Activated Protein C Action in Sepsis Therapy
-
批准号:7883310
-
项目类别:
-
资助金额:$40.61万
-
财政年份:2008
-
负责人:Hartmut Karl-Heinz Weiler
-
依托单位:
Activated Protein C for Treatment of Radiation Combined Injury
-
批准号:7559919
-
项目类别:
-
资助金额:$27.9万
-
财政年份:2008
-
负责人:Hartmut Karl-Heinz Weiler
-
依托单位:
Activated Protein C for Treatment of Radiation Combined Injury
-
批准号:7651281
-
项目类别:
-
资助金额:$16.71万
-
财政年份:2008
-
负责人:Hartmut Karl-Heinz Weiler
-
依托单位:
Mechanism of Activated Protein C Action in Sepsis Therapy
-
批准号:7689753
-
项目类别:
-
资助金额:$40.29万
-
财政年份:2008
-
负责人:Hartmut Karl-Heinz Weiler
-
依托单位:
Activated Protein C for Treatment of Radiation Combined Injury
-
批准号:8142112
-
项目类别:
-
资助金额:$41.44万
-
财政年份:2008
-
负责人:Hartmut Karl-Heinz Weiler
-
依托单位:
Activated Protein C for Treatment of Radiation Combined Injury
-
批准号:8311572
-
项目类别:
-
资助金额:$40.61万
-
财政年份:2008
-
负责人:Hartmut Karl-Heinz Weiler
-
依托单位:
Mechanism of Activated Protein C Action in Sepsis Therapy
-
批准号:8105326
-
项目类别:
-
资助金额:$40.61万
-
财政年份:2008
-
负责人:Hartmut Karl-Heinz Weiler
-
依托单位:
Activated Protein C for Treatment of Radiation Combined Injury
-
批准号:8138839
-
项目类别:
-
资助金额:$41.82万
-
财政年份:2008
-
负责人:Hartmut Karl-Heinz Weiler
-
依托单位:
Transgenic/Knockout Core
-
批准号:7140698
-
项目类别:
-
资助金额:$2.31万
-
财政年份:2005
-
负责人:Hartmut Karl-Heinz Weiler
-
依托单位:
国内基金
海外基金
登录
查看更多内容
Epac1/2通过蛋白酶体调控中性粒细胞NETosis和Apoptosis在急性肺损伤中的作用研究
-
批准号:LBY21H010001
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2020
-
负责人:郑绪阳
-
依托单位:
去乙酰化酶SIRT1在前体mRNA可变剪切中的作用及其生理病理效应研究
-
批准号:31970691
-
项目类别:面上项目
-
资助金额:58.0万元
-
批准年份:2019
-
负责人:张胜萍
-
依托单位:
TM9SF4调控非小细胞肺癌细胞凋亡机制研究
-
批准号:31900527
-
项目类别:青年科学基金项目
-
资助金额:24.0万元
-
批准年份:2019
-
负责人:孙磊
-
依托单位:
基于Apoptosis/Ferroptosis双重激活效应的天然产物AlbiziabiosideA的抗肿瘤作用机制研究及其结构改造
-
批准号:81703335
-
项目类别:青年科学基金项目
-
资助金额:20.0万元
-
批准年份:2017
-
负责人:卫高菲
-
依托单位:
双肝移植后Apoptosis和pyroptosis在移植物萎缩差异中的作用和供受者免疫微环境变化研究
-
批准号:81670594
-
项目类别:面上项目
-
资助金额:58.0万元
-
批准年份:2016
-
负责人:陈昊
-
依托单位:
Serp-2 调控apoptosis和pyroptosis 对肝脏缺血再灌注损伤的保护作用研究
-
批准号:81470791
-
项目类别:面上项目
-
资助金额:73.0万元
-
批准年份:2014
-
负责人:董家鸿
-
依托单位:
Apoptosis signal-regulating kinase 1是七氟烷抑制小胶质细胞活化的关键分子靶点?
-
批准号:81301123
-
项目类别:青年科学基金项目
-
资助金额:23.0万元
-
批准年份:2013
-
负责人:王海莲
-
依托单位:
姜黄素与TRAIL的协同抗肿瘤机制研究
-
批准号:31101223
-
项目类别:青年科学基金项目
-
资助金额:24.0万元
-
批准年份:2011
-
负责人:曹林
-
依托单位:
转凝蛋白通过线粒体凋亡途径致足细胞凋亡的机制研究
-
批准号:81100502
-
项目类别:青年科学基金项目
-
资助金额:23.0万元
-
批准年份:2011
-
负责人:管娜
-
依托单位:
APO-miR(multi-targeting apoptosis-regulatory miRNA)在前列腺癌中的表达和作用
-
批准号:81101529
-
项目类别:青年科学基金项目
-
资助金额:22.0万元
-
批准年份:2011
-
负责人:陈雪芹
-
依托单位: